Sanofi-aventis enters into an Exclusive Global Licensing Agreement with The Rockefeller University
- Details
- Category: Sanofi
Sanofi-aventis (EURONEXT: SAN and NYSE: SNY) announced an exclusive global licensing agreement with The Rockefeller University (New York, NY) concerning a novel monoclonal antibody, targeting certain specific forms of the Amyloid Beta parenchymal plaque for the treatment of Alzheimer's disease.
New Amgen Scholars Web site Launches to Build a Global Network for Future Scientists
- Details
- Category: Amgen
Each year, hundreds of undergraduate students from across the United States (U.S.) and Europe participate in the Amgen Scholars Program to gain hands-on laboratory experience under renowned faculty members at the world's leading universities. Now, the Amgen Scholars - past, present and future - will have exclusive access to the online Amgen Scholars Community.
AstraZeneca and Targacept Form Global Collaboration and Licence Agreement
- Details
- Category: AstraZeneca
AstraZeneca and Targacept, Inc. announced a collaboration and licence agreement for the global development and commercialisation of TC-5214, Targacept's late-stage investigational product for major depressive disorder (MDD). TC-5214, which recently completed a phase IIb clinical trial, is a nicotinic channel blocker that is thought to treat depression by modulating the activity of various neuronal nicotinic receptor (NNR) subtypes.
Resource Guide About Key Issues Facing the Pharmaceutical Industry
- Details
- Category: Eli Lilly and Company
The educational resource, "The Value of Medicine, Improving Health... Improving Life," created by Lilly USA (NYSE: LLY), is now available for download. The booklet supports Lilly's commitment to providing "Answers That Matter" and encourages an open dialogue with patients, providers, payers and the public about pharmaceutical industry practices.
GSK's Arepanrix⢠H1N1 pandemic vaccine prequalified by the World Health Organization
- Details
- Category: GlaxoSmithKline
GlaxoSmithKline (GSK) announced that the World Health Organization (WHO) has awarded prequalification for global use of Arepanrix™, GSK's adjuvanted H1N1 pandemic vaccine manufactured in Canada. This is the first prequalification for an H1N1 pandemic vaccine, and is a key step in ensuring the vaccine can be distributed to developing countries.
Merck KGaA Receives Refuse to File Letter from FDA on Cladribine Tablets New Drug Application
- Details
- Category: Merck Group
Merck KGaA announced that its US affiliate received a refuse to file letter from the US Food and Drug Administration (FDA) on the New Drug Application (NDA) for Cladribine Tablets, Merck Serono's proprietary investigational oral formulation of cladribine, as a therapy for relapsing forms of multiple sclerosis (MS).
Pfizer And Protalix Enter Into Agreement To Develop And Commercialize Gaucher's Disease Treatment
- Details
- Category: Pfizer
Pfizer (NYSE: PFE) and Protalix (NYSE-Amex: PLX) have entered into an agreement to develop and commercialize taliglucerase alfa, a plant-cell expressed form of glucocerebrosidase (GCD) in development for the potential treatment of Gaucher's disease.
More Pharma News ...
- "Positive Charge" to Help Address Barriers and Provide Support to People Living with HIV/AIDS
- Bayer Starts Phase III Trial with Florbetaben
- Bayer starts pivotal Phase III trial with Florbetaben
- Novartis gains rights to two oral targeted investigational therapies
- Lundbeck initiates clinical phase II trials with Lu AE58054
- FDA Grants IBsolvMIR Orphan Drug designation in the treatment of diabetes patients in the U.S.
- Novartis inaugurates large-scale US based cell-culture influenza vaccine manufacturing facility